Adrenocortical carcinoma

Current Opinion in Oncology

Volumn 18, Issue 1, 2006, Pages 36-42

  Roman, Sanziana ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F fluorodeoxyglucose positron emission tomography; Activin; Adrenocortical carcinoma; Inhibin; Mitotane pediatric adrenocortical carcinoma; Vascular endothelial growth factor

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; CARBON 11; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; METOMIDATE; MITOTANE;

ADRENAL CORTEX; ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; AUTOCRINE EFFECT; CANCER REGISTRY; CARCINOGENESIS; HUMAN; LIVER METASTASIS; PARACRINE SIGNALING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VIRILIZATION;

ACTIVINS; ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; INHIBINS; MITOTANE; POSITRON-EMISSION TOMOGRAPHY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646683536     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000198976.43992.14     Document Type: Review

References (38)

1. Vaughan ED. Diseases of the adrenal gland. Med Clin N Am 2004; 88:443-466.
2. Dackiw AP, Lee JE, Gagel RF, et al. Adrenal cortical carcinoma. World J Surg 2001; 25:914-926.
3. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001; 25:891-897.
4. Tauchmanova L, Colao A, Marzano LA, et al. Adrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004; 28:896-903.
5. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. N Engl J Med 1990; 322:1195-1200.
6. Imperato MJ, Young IS, Huang T, et al. Testosterone secreting adrenal cortical adenomas. Int J Gynaecol Obstet 1981; 19:421-424.
7. Luscher T, Tenschert W, Salvetti A, et al. Primary aldosteronism due to adrenal carcinomas. Klin Wochenschr 1984; 62:470-477.
8. Seccia TM, Fassina A, Nussdorfer GG, et al. Aldosterone-producing adrenalcortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocrine-Related Cancer 2005; 12:149-159.
9. Mussig K, Wehrmann M, Horger M, et al. Adrenocortical carcinoma producing 11-deoxycorticosterone: a rare cause of mineralocorticoid hypertension. J Endocrinol Invest 2005; 28:61-65.
10. Karakousis CP, Rao V, Moore R. Adrenal adenocarcinomas: histologic grading survival. J Surg Oncol 1985; 29:105-111.
11. Kurtulmus N, Yarman S, Azizlerli H, Kapran Y. Co-secretion of aldosterone and cortisol by an adrenocortical carcinoma. Hormone Res 2004; 62:67-70.
12. Chen DY, Sosa RE, Scherr DS. Treatment of adrenocortical carcinoma: contemporary outcomes. Current Urology Reports 2004; 5:65-72.
13. Boulle N, Logie A, Gicquel C, et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998; 83:1713-1718.
14. Beuschlein F, Looyenga BD, Reincke M, et al. Role of inhibin/activin system and luteinizing hormone in adrenocortical tumorigenesis. Horm Metab Res 2004; 36:392-396. An original study of paracrine and autocrine hormonal effects in adrenal cortical differentiation and tumorigenesis.
15. Sarkaria IS, Stojadinovic A, Talbot S, et al. Squamous cell carcinoma-related oncogene is highly expressed in developing, normal, and adenomatous adrenal tissue but not in adrenocortical carcinomas. Surgery 2004; 136:1122-1129.
16. Zaharieva S, Atanassova I, Orbetzova M, et al. Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. Eur J Endocrinol 2004; 150:345-349.
17. Kolomecki K, Stepien H, Bartos M, et al. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocrine Regulation 2001; 35:9-16.
18. Ljungberg B, Jacobsen J, Haggstrom-Rudolfsson S, et al. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res 2003; 31:335-340.
19. Erickson LA, Lloyd RV, Hartman R, et al. Cystic adrenal neoplasms. Cancer 2004; 101:1537-1544.
20. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delay contrast-enhanced CT. Radiology 2005; 234:479-485.
21. Tenenbaum F, Groussin L, Foehrenbach H, et al. F-Fluorodeoxyglucose positron emission tomography as a diagnositic tool for malignancy of adrenocortical tumors? Preliminary results in 13 consecutive patients. Eur J Endocrinol 2004; 150:789-792.
22. 11C-metomidate. Eur J Nucl Med Mol Imaging 2004; 31:1221-1230.
23. Slapa RZ, Kasperlik-Zaluska AA, Polanski JA, et al. Three-dimensional sonography in diagnosis of retroperitoneal hemorrhage from adrenocortical carcinoma. J Ultrasound Med 2004; 23:1369-1373.
24. Sturgeon C, Kebebew E. Laparoscopic adrenalectomy for malignancy. Surg Clin N Am 2004; 84:755-774.
25. Tauchmanova L, Colao A, Marzano LA, et al. Adrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004; 28:896-903.
26. Walz MK, Petersenn S, Kock JA, et al. Endoscopic treatment of large primary adrenal tumours. Brit J Surg 2003; 92:719-723.
27. Barnett CC, Varma DG, El-Naggar AK, et al. Limitations of size as a criterionin the evaluation of adrenal tumors. Surgery 2000; 128:973-982.
28. Weitz J, Blumgart LH, Fong Y, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg 2005; 241:269-276.
29. Meyer A, Niemann U, Behrend M. Experience with the surgical treatment of adrenal cortical carcinoma. Eur J Surg Onc 2004; 30:444-449.
30. Li SH, Huang CH, Ko SF. Extended survival in a patient with recurrent and metastatic adrenal cortical carcinoma by aggressive transarterial embolizations. J Surg Onc 2005; 90:101-105.
31. Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003; 97:554-560.
32. Pommier R, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112:963-971.
33. Haak HR, Hermans J, Van de Valde CJH, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69:947-953.
34. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998; 83:2194-2200.
35. Ahlman H, Khorram-Manesh A, Jansson S, et al. Cytotoxic treatment of adrenocortical carcinoma. World J Surg 2001; 25:927-933.
36. MacFarlane D. Cancer of the adrenal cortex: the natural history, prognosis, and treatment in a study of 55 cases. Ann R Coll Surg Engl 1958; 23:155.
37. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Onc 2004; 22:838-845. This study is a comprehensive analysis specifically focused on ACC in the pediatric population. It is the largest study to date looking at incidence, biochemical diagnosis, surgical and adjuvant treatment of ACC as well as independent predicting factors affecting survival.
38. Betz MJ, Shapiro I, Fassnacht M, et al. Peroxisome proliferators- activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol and Metab 2005; 90:3886-3896.